Topic
Design and delivery of synthetic messenger RNA for vaccines, cancer immunotherapy and protein-replacement treatment.
Georgia Tech and Emory researchers found the gut site where a lipid-nanoparticle mRNA dose lands, cheek to rectum, changes which organs it reaches in mice. That turns the delivery site into a tool for aiming oral vaccines at lymph nodes or GLP-1 therapy at the pancreas.
Reality
Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.
Perspective Coverage
6 publishersReality
Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.
Perspective Coverage
3 publishersReality
The companies say intismeran plus Keytruda slowed melanoma's return after surgery in the first randomized Phase 3 test of neoantigen vaccines. No detailed data has been released.
Perspective Coverage
4 publishersReality
Ninety percent of drug candidates that reach human trials are never approved. A Norwegian group argues some of that triage belongs in donor blood, where nanoparticles meet the plasma proteins and immune cells that settle their fate.
Reality
Johns Hopkins and NIH researchers report faster, cleaner translation from an alternative mRNA modification than from the chemistry used in COVID-19 mRNA vaccines. Dose economics is the open question.
Reality
In mice, a peptide-PEG agent given before dosing cut liver expression several dozenfold and raised spleen expression severalfold, according to work in ACS Nano.
Reality
A screen of 337 virus genomes found stabilizing elements; one, Pt1, pushed linear mRNA half-life from 7.6 to 23.1 hours by recruiting nuclear poly(A) polymerases in the cytoplasm.
Reality